Faculty Profiles - NISHIDA Keiichiro

Papers - NISHIDA Keiichiro

Division display 121 - 140 of about 642 ／ All the affair displays >>

人工手関節置換術後のゆるみに対して他家骨移植を併用した全人工手関節固定術を施行した1例

那須義久, 西田圭一郎, 中原龍一, 浪花崇一, 堀田佳史, 尾崎敏文

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 616 - 616 2022.3

その他の(多彩な)膠原病機械学習を用いたサマリー自動可視化システムによるサマリー記載の標準化

中原龍一, 西田圭一郎, 高橋康, 浪花崇一, 堀田佳史, 那須義久, 尾崎敏文

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 477 - 477 2022.3

人工肘関節全置換術を施行した関節リウマチ患者の上肢機能に影響を与える因子の検討

松山宜之, 那須義久, 原田遼三, 中原龍一, 西田圭一郎, 尾崎敏文, 千田益生

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 636 - 636 2022.3

関節リウマチ患者に対する連結型人工肘関節全置換術(PROSNAP)の臨床成績の検討

堀田佳史, 西田圭一郎, 浪花崇一, 原田遼三, 中原龍一, 那須義久, 尾崎敏文

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 618 - 618 2022.3

フットケア外来を通じ手術治療機会を得た高齢RA患者の一例

井上るみ, 原田遼三, 高杉幸司, 江澤和彦, 井上貴絵, 藤田慎一朗, 新名早希子, 山本渉, 中原龍一, 那須義久, 西田圭一郎

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 731 - 731 2022.3

JAK阻害薬継続下にCOVID-19ワクチン接種を行った症例の経過について症例報告

原田遼三, 高杉幸司, 江澤和彦, 井上貴絵, 藤田慎一朗, 井上るみ, 新名早希子, 山本渉, 中原龍一, 那須義久, 西田圭一郎

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 701 - 701 2022.3

リウマチ患者に対する母指MCP人工関節置換術の長期成績

兼田大輔, 西田圭一郎, 那須義久, 中原龍一, 渡辺雅仁, 堀田佳史, 浪花崇一

日本整形外科学会雑誌 96 ( 2 ) S139 - S139 2022.3

リウマチ性疾患の上肢手術リウマチ母指に対する母指MCP人工関節置換術の長期成績

兼田大輔, 西田圭一郎, 那須義久, 中原龍一, 原田遼三, 渡辺雅仁, 堀田佳史, 浪花崇一

日本リウマチ学会総会・学術集会プログラム・抄録集 66回 352 - 352 2022.3

Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis International journal

Hiromu Ito, Koichi Murata, Yasumori Sobue, Toshihisa Kojima, Keiichiro Nishida, Isao Matsushita, Yutaka Kawahito, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Masayoshi Harigai

Modern Rheumatology 32 ( 2 ) 296 - 306 2022.2

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Objectives

To examine the risk factors of surgical site infection (SSI), delayed wound healing, and death after orthopedic surgery in patients with rheumatoid arthritis (RA).

Methods

We identified articles indexed in the Cochrane Library, PubMed, and Japan Centra Revuo Medicina Web published from 2013 to 2019 and other articles. Articles fulfilling the predefined inclusion criteria were reviewed systematically and their quality was appraised according to the Grading of Recommendations Assessment, Development, and Evaluation system with some modifications.

Results

After inclusion and exclusion by full-text review, 29 articles were analyzed. Use of biological disease modifying antirheumatic drugs was a risk factor of SSI (risk ratio 1.66, 95% confidence interval 1.25–2.19), but not of delayed wound healing. RA itself was a risk factor of SSI, and oral glucocorticoid use was a risk factor of SSI in three of the four studies analyzed and of postoperative death. Age, male sex, comorbidities such as diabetes mellitus and chronic obstructive pulmonary disease, surgical factors such as foot/ankle and spine surgery and longer operative time were risk factors of those postoperative complications.

Conclusion

Patients with those factors should be dealt with appropriate cautions to strike a risk–benefit balance of orthopedic surgeries.

DOI： 10.1080/14397595.2021.1913824

PubMed

researchmap

Other Link： https://academic.oup.com/mr/article-pdf/32/2/296/42644947/1913824.pdf

Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis International journal

Takahiko Sugihara, Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Yohei Seto, Toshihisa Kojima, Hiromu Ito, Masataka Kohno, Takeo Nakayama, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Atsuko Murashima, Masaaki Mori, Eiichi Tanaka, Shintaro Hirata, Mitsumasa Kishimoto, Hisashi Yamanaka, Masayo Kojima, Masayoshi Harigai

Modern Rheumatology 32 ( 2 ) 313 - 322 2022.2

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Objectives

To provide an evidence base for clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA) in older adults.

Methods

PubMed, Cochrane library, and Japan Centra Revuo Medicina databases were searched for articles published between 1990 and 2019. Quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation system, with some modifications.

Results

Among 702 identified articles, there were 5 post-hoc analyses of randomized controlled trials and 10 observational studies. Meta-analysis of the former yielded a mean difference of the van der Heijde-modified total Sharp score of −2.79 (95% confidence interval [CI] − 3.74 to −1.84) for treatment with tumor necrosis factor inhibitors. The risk ratio (RR) for the American College of Rheumatology 50% response rate, and for serious adverse events was 2.83 (95%CI 1.90–4.21) and 1.32 (95%CI 0.53–3.31), respectively, for Janus kinase inhibitors. Meta-analysis of the observational studies yielded an RR for disease activity score-28 remission and serious infections of 0.76 (95%CI 0.64–0.91) and 1.92 (95%CI 1.31–2.81) for older-versus-younger patients receiving biological disease-modifying antirheumatic drugs, respectively.

Conclusion

This systematic review provides the necessary evidence for developing CPG for the management of RA in older adults.

DOI： 10.1080/14397595.2021.1912922

PubMed

researchmap

Other Link： https://academic.oup.com/mr/article-pdf/32/2/313/42644941/1912922.pdf

Patients’ perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines International journal

Masayo Kojima, Mieko Hasegawa, Shintaro Hirata, Hiromu Ito, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Toshihisa Kojima, Isao Matsushita, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Keiichiro Nishida, Yohei Seto, Yasumori Sobue, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Yutaka Kawahito, Masayoshi Harigai

Modern Rheumatology 32 ( 2 ) 307 - 312 2022.2

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Objectives

This study aimed to evaluate patients’ opinions regarding their rheumatoid arthritis (RA) therapy and to reflect the patients’ perspectives in the 2020 update of the Japan College of Rheumatology clinical practice guidelines.

Methods

A self-administered questionnaire was mailed to 1600 members of the Japan Rheumatology Friendship Association, who were randomly selected by age and prefecture.

Results

A total of 1156 patients returned the questionnaire (response rate, 72.3%; mean age, 63.0 ± 11.9 years). Those who reported having discussed their treatment goals with their doctors (450 respondents, 38.9%) were more likely to be satisfied with their current medical care (odds ratio, 7.13; 95% CI 4.72–10.8) compared with those who had not discussed their goals nor had them explained (287 respondents, 24.8%). The benefits exceeded the adverse effects for all pharmacotherapy (methotrexate, corticosteroids, conventional synthetic antirheumatic drugs, biological agents, Janus kinase inhibitor, and anti-RANKL antibodies). However, while 74.2% of the respondents using biological agents perceived that ‘the favorable aspects outweighed the unfavorable aspects,’ most of those taking anti-RANKL antibodies (69.2%) felt uncertain.

Conclusions

The questionnaire successfully collected information regarding patients’ perceptions regarding their therapy. Further implementation of treat-to-target is necessary in Japan to improve patient satisfaction.

DOI： 10.1080/14397595.2021.1913276

PubMed

researchmap

Other Link： https://academic.oup.com/mr/article-pdf/32/2/307/42644853/1913276.pdf

CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice Reviewed International journal

Minami Matsuhashi, Keiichiro Nishida, Misa Sakamoto, Yuka Gion, Aki Yoshida, Takayuki Katsuyama, Ryuichi Nakahara, Yoshihisa Nasu, Yoshinori Matsumoto, Yasuharu Sato, Toshifumi Ozaki

Inflammation Research 71 ( 2 ) 215 - 226 2022.2

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC

OBJECTIVE: It has been reported that levels of soluble CD30 in serum and joint fluid are significantly elevated in patients with rheumatoid arthritis (RA). This study aimed to investigate whether CD30 could be a therapeutic target for RA. METHODS: The expression and localization of CD30 were examined by immunohistochemical and double immunofluorescence staining on synovial tissue samples obtained from patients with RA or osteoarthritis (OA) during surgery. Changes in CD30 expression of fibroblast-like synoviocytes (FLS) from RA patients with or without TNFα and IL-1β stimulation were examined by the polymerase chain reaction (PCR) and flow cytometry. Collagen antibody-induced arthritis (CAIA) was created in DBA/1 mice, and the therapeutic effect of brentuximab vedotin (BV) was examined by clinical score, histological findings and measurement of serum levels of SAA, IL-6, and TNFα. RESULTS: CD30 expression was significantly higher in samples from patients with RA than from those with OA. Double immunofluorescence showed a low rate of co-localization of CD30 with CD20 or CD90, but a high rate of co-localization of CD30 and CD138. CD30 mRNA expression was upregulated 11.7-fold in FLS following stimulation by inflammatory cytokines. The clinical scores of CAIA mice were significantly lower following both BV treatments, however, the histological scores of CAIA mice were significantly lower only following treatment with high dose BV (70 mg/kg). CONCLUSIONS: CD30 was expressed on immunocompetent cells in synovial tissue from RA patients and in cytokine-stimulated FLS in vitro. High dose BV (70 mg/kg) showed significant therapeutic effects in ameliorating inflammation and joint destruction in CAIA mice, but low dose BV (30 mg/kg) was insufficient.

DOI： 10.1007/s00011-021-01537-z

PubMed

researchmap

Other Link： https://link.springer.com/article/10.1007/s00011-021-01537-z/fulltext.html

Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines International journal

Yasumori Sobue, Masayo Kojima, Toshihisa Kojima, Hiromu Ito, Keiichiro Nishida, Isao Matsushita, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Atsuko Murashima, Akio Morinobu, Masaaki Mori, Takeo Nakayama, Takahiko Sugihara, Yohei Seto, Eiichi Tanaka, Mieko Hasegawa, Yutaka Kawahito, Masayoshi Harigai

Modern Rheumatology 32 ( 1 ) 121 - 126 2022.1

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Objective

This study aimed to evaluate satisfaction with total joint replacement (TJR) surgery among patients with rheumatoid arthritis (RA).

Methods

We mailed questionnaires to randomly selected members of the Japan Rheumatism Friendship Association, stratified by age and prefecture, throughout Japan. The questionnaire collected demographic and clinical characteristics as well as patients’ satisfaction with TJR and their current therapy.

Results

Of the 1156 patients who returned the questionnaire, 339 (29.3%) responded that they had had TJR of any type. The mean age was 66.6 years, and 94.4% were women. The mean time period from the hip and knee TJR was 14–15 years. Over half of the patients who had had TJR were satisfied with the results, especially those who had had hip (89.6%) and knee TJR (87.3%), who reported a high level of satisfaction. Multivariable linear regression analysis revealed that, in patients with knee TJR, satisfaction with current therapy was significantly related to whether they were satisfied with the results of the surgery.

Conclusion

Most patients with RA who had undergone TJR were satisfied with the results even after a long period of time, and their level of satisfaction was associated with their satisfaction with current therapy.

DOI： 10.1080/14397595.2021.1892258

PubMed

researchmap

Other Link： https://academic.oup.com/mr/article-pdf/32/1/121/42083431/1892258.pdf

Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis International journal

Eiichi Tanaka, Yutaka Kawahito, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yuko Kaneko, Hiroya Tamai, Yohei Seto, Akio Morinobu, Takahiko Sugihara, Atsuko Murashima, Masayo Kojima, Masaaki Mori, Hiromu Ito, Toshihisa Kojima, Yasumori Sobue, Keiichiro Nishida, Isao Matsushita, Takeo Nakayama, Hisashi Yamanaka, Masayoshi Harigai

Modern Rheumatology 32 ( 1 ) 74 - 86 2022.1

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Objectives

To evaluate the efficacy and safety of biosimilars compared with reference biological disease modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) as a part of the process of developing the 2020 update of the Japan College of Rheumatology guidelines for the management of RA.

Methods

PubMed, Cochrane Library, and Japan Centra Revuo Medicina were searched for articles to conduct a systematic review (SR). The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation system.

Results

Twenty randomized controlled trials were included (biosimilars of infliximab, etanercept, and adalimumab). A meta-analysis revealed that the risk ratios (RRs) and 95% confidence intervals (CIs) of achieving the American College of Rheumatology 50% response (ACR50) at week 24 and serious adverse events (SAEs) for biosimilars compared with the reference bDMARDs were 1.04 (0.98–1.10) and 0.84 (0.61–1.18), respectively. The RRs of achieving ACR50 and SAEs at week 24 were respectively 0.93 (0.69–1.26) and 2.15 (0.55–8.35) in the patients who switched to biosimilars from the reference bDMARDs and 0.92 (0.76–1.12) and 1.41 (0.32–6.15) in those who continued the reference bDMARDs.

Conclusion

Biosimilars and reference bDMARDs were equally useful for the management of RA.

DOI： 10.1080/14397595.2021.1899591

PubMed

researchmap

Other Link： https://academic.oup.com/mr/article-pdf/32/1/74/42083415/1899591.pdf

Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis International journal

Yasumori Sobue, Toshihisa Kojima, Hiromu Ito, Keiichiro Nishida, Isao Matsushita, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Takahiko Sugihara, Yohei Seto, Eiichi Tanaka, Takeo Nakayama, Shintaro Hirata, Atsuko Murashima, Akio Morinobu, Masaaki Mori, Masayo Kojima, Yutaka Kawahito, Masayoshi Harigai

Modern Rheumatology 32 ( 1 ) 96 - 104 2022.1

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Objectives

This study aimed to evaluate the impact of exercise therapy on patient-reported outcomes (PROs) in rheumatoid arthritis (RA) as part of the process of updating the 2020 Japanese guidelines for the management of RA according to the Grading of Recommendations, Assessment, Development, and Evaluation system.

Methods

We searched PubMed, Japana Centra Revuo Medicina Web, and the Cochrane Library (from 2009 to 2018) to identify articles that evaluated PROs of exercise therapy and RA disease activity.

Results

A total of 662 articles were identified, including nine RCTs, and meta-analyses were performed on six RCTs on systemic exercise therapy and three RCTs on upper extremity exercise therapy. Analyzed exercise therapies were diverse, differing in target population, intervention method, and duration. Significant improvements were observed in the Health Assessment Questionnaire Disability Index (mean difference −0.35, 95% confidence interval (CI): −0.60 to −0.10), pain (standardized mean difference −2.04, 95% CI: −3.77 to −0.32), and SF-36. For upper extremity exercise therapy, significant improvements in PROs (Disabilities of the Arm, Shoulder, and Hand Questionnaire, Michigan Hand Outcome Questionnaire) were observed.

Conclusion

Exercise therapy in RA treatment improves patient subjective assessment of pain, physical function, and quality of life.

DOI： 10.1080/14397595.2021.1886653

PubMed

researchmap

Other Link： https://academic.oup.com/mr/article-pdf/32/1/96/42083491/1886653.pdf

Subjective and Objective Outcomes of Surgery for Rheumatoid Forefoot Deformities Under the Current Treatment Paradigm International journal

Masahiro Horita, Keiichiro Nishida, Daisuke Kaneda, Kenzo Hashizume, Yoshihisa Nasu, Ryuichi Nakahara, Kenta Saiga, Hideki Ohashi, Masahito Watanabe, Toshifumi Ozaki

The Journal of Foot and Ankle Surgery 61 ( 1 ) 53 - 59 2022.1

Language：English Publishing type：Research paper (scientific journal) Publisher：Elsevier BV

We investigated the clinical outcomes of surgical procedures for the treatment of forefoot deformities in patients with rheumatoid arthritis. Twenty feet in 16 women (mean age 62.1 years) underwent corrective osteotomy of the first metatarsal bone with shortening oblique osteotomy of the lesser metatarsophalangeal joints (joint-preservation group), while 13 feet in 12 women (mean age 67.4 years) underwent arthrodesis of the first metatarsophalangeal joint with resection arthroplasty of the lesser metatarsophalangeal joints (joint-sacrifice group); mean follow-up for each group was 25.8 and 23.8 months, respectively. The mean total Japanese Society for Surgery of the Foot (JSSF) scale improved significantly from 64.2 to 89.2 in the joint-preservation group (p < .001), and from 54.2 to 74.2 in the joint-sacrifice group (p = .003). In the joint-preservation group, the postoperative range of motion (ROM) of the joint, walking ability, and activities of daily living scores of the JSSF scale were significantly higher than those in the joint-sacrifice group (p = .001, p = .001, and p = .019, respectively). There were no differences in the subscale scores of the self-administered foot evaluation questionnaire between 2 groups either pre- or postoperatively. No differences in the postoperative complications were found between 2 groups. Although the joint-sacrificing procedure resulted in lower objective outcomes than the joint-preserving procedure regarding the ROM of the joint, the walking ability, and the level of activities of daily living, both procedures resulted in similar treatment outcomes when evaluated by the subjective measures.

DOI： 10.1053/j.jfas.2021.06.008

PubMed

researchmap

Outcome after resection arthroplasty or shortening oblique osteotomy of the lesser metatarsals combined with arthrodesis of the first metatarsophalangeal joint for severe rheumatoid forefoot deformities Reviewed International journal

Masahiro Horita, Keiichiro Nishida, Yoshihisa Nasu, Ryuichi Nakahara, Kenta Saiga, Masanori Hamada, Toshifumi Ozaki

Journal of Orthopaedic Surgery 30 ( 2 ) 102255362211179 - 102255362211179 2022.1

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：SAGE Publications

Purpose

We investigated objective and patient-reported outcomes after resection arthroplasty or shortening oblique osteotomy (SOO) of the lesser metatarsals combined with arthrodesis of the first metatarsophalangeal (MTP) joint for severe rheumatoid forefoot deformities.

Methods

17 feet from 14 women (mean age, 67.8 years) underwent resection arthroplasty of the lesser metatarsal heads (MTH resection group), while 13 feet from nine women and two men (mean age, 68.7 years) underwent SOO of the lesser metatarsals (MTH preservation group). Arthrodesis of the first MTP joint was performed in all cases. Mean follow-up in the MTH resection and preservation groups was 25.0 and 21.3 months, respectively. Preoperative and postoperative clinical evaluation included Japanese Society for Surgery of the Foot (JSSF) scale and self-administered foot evaluation questionnaire (SAFE-Q) scores.

Results

Mean total JSSF scale significantly improved from 53.4 to 76.4 in the MTH resection group ( p < .001) and from 50.1 to 74.2 in the MTH preservation group ( p = .002). Pain and pain-related and shoe-related SAFE-Q subscale scores significantly improved after surgery in both groups. In the MTH resection group, recurrence of painful callosities and claw toe deformity was observed in four and three feet, respectively. In the MTH preservation group, one patient experienced recurrence of painful callosities and one underwent revision surgery for IP joint dislocation.

Conclusion

Resection arthroplasty or SOO of the lesser metatarsals combined with arthrodesis of the first MTP joint achieved significant improvement with respect to pain relief, deformity correction, and footwear comfort.

DOI： 10.1177/10225536221117903

PubMed

researchmap

Other Link： http://journals.sagepub.com/doi/full-xml/10.1177/10225536221117903

上腕筋三頭筋温存アプローチ用いてPROSNAP人工肘関節置換術を施行した症例

堀田佳史, 西田圭一郎, 志水紀之, 中原龍一, 那須義久, 尾崎敏文

関節の外科 49 ( 2 ) 106 - 106 2022